Gain Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended March 31, | ||||||
| · 2025 · 2024 | ||||||
| · · · · | ||||||
| Operating activities: · · | ||||||
| Net loss | | $(4,530,058) | | $(4,014,194) | ||
| | | | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | ||||
| Depreciation and amortization | | 20,660 | | 20,528 | ||
| Stock based compensation expense | | 419,504 | | 190,424 | ||
| Other non-cash items | | | 109,591 | | | (200,146) |
| | | | | | | |
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other current assets | | | (844,484) | | | (295,447) |
| Long term deposit and other noncurrent assets | | 927 | | (3,021) | ||
| Accounts payable and other current liabilities | | 1,114,140 | | 703,593 | ||
| Defined benefit pension plan | | | (23,176) | | | (30,118) |
| Deferred grant income | | (88,631) | | 41,798 | ||
| Total changes in operating assets and liabilities | | | 158,776 | | | 416,805 |
| Cash used in operating activities | | | (3,821,527) | | | (3,586,583) |
| | | | | | | |
| Cash flows from investing activities: | | | | |||
| Maturities of marketable securities | | | — | | | 3,018,750 |
| Cash provided by investing activities | | | — | | | 3,018,750 |
| | | | | | | |
| Cash flow from financing activities: | | | | |||
| Net proceeds from issuance of shares in ATM offering (Note 14) | | 2,419,320 | | — | ||
| Net proceeds from the exercise of warrants (Note 14) | | | — | | | 100,225 |
| Net proceeds from the exercise of stock options (Note 15) | | | — | | | 57,711 |
| Payments of offering costs (Note 14) | | | — | | | (280,867) |
| Payments of current portion of long-term debt (Note 12) | | | (22,242) | | | (22,872) |
| Cash provided by (used in) financing activities | | | 2,397,078 | | | (145,803) |
| Effect of exchange rate changes | | | 109,535 | | | (442,503) |
| Net decrease in cash, cash equivalents and restricted cash | | | (1,314,914) | | | (1,156,139) |
| Cash, cash equivalents and restricted cash at beginning of period | | 10,417,558 | | 11,828,970 | ||
| Cash, cash equivalents and restricted cash at end of period | | $9,102,644 | | $10,672,831 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.